

New test

Test name:	Next generation sequencing (NGS)
Test #:	Pathology add on
Notification date:	December 15, 2020
Effective date:	Immediately

Allina Health Laboratory is pleased to share that we are now offering Next Generation Sequencing (NGS) for the detection of alterations in solid tumors. Identification of these alterations is critical for cancer care as these findings can direct the optimal use of targeted therapies for patients.

Several subpanels based on tumor specific needs can be ordered. These include panels for Lung cancer, colorectal cancer, melanoma, gastrointestinal stromal tumors and others. In addition, the full panel of 52 genes or custom panels can be requested.

Lung:

- Lung adenocarcinoma targeted NGS panel: ALK, BRAF, EGFR, ERBB2, KRAS, HRAS, MET, NRAS, NTRK1/2/3, RET, ROS1
- Lung squamous cell carcinoma targeted NGS panel: BRAF, NTRK1/2/3

Gastrointestinal/Colorectal:

- Extended RAS/RAF NGS panel: BRAF, KRAS, NRAS, HRAS
- GIST targeted NGS panel: KIT, PDGFRA, BRAF

Melanoma:

- Melanoma targeted NGS panel: BRAF, KIT, NRAS, GNA11, GNAQ
- Melanoma BRAF NGS assay: BRAF only

Additional options:

- Solid tumor targeted NGS panel: 52 genes
- A la Carte NGS custom gene order

This testing is subject to Medical Necessity and may require preauthorization from insurance providers. Check the payer guidelines and, if needed, obtain the pre-authorization prior to sample collection.

The Allina Health Laboratory test catalog and Pathology add on test requests have been updated to include details for this new testing. Please place an order for updated requisitions and discard the old upon receipt.

If you have questions and would like to speak with one of our molecular pathologists regarding these tests, please call (612) 863-4670 and ask for Dr. Sarah Kerr or Dr. John Reinartz.